The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://kathrynkllk359657.wiki-cms.com/8136198/glp_3_retatrutide_a_comparative_analysis